Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin‐Biroulet, Peter Bossuyt, Matthieu Allez et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 96
Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative ColitisRaja Atreya, C J Hawkey, Stuart Bloom et al.|Journal of Crohn s and Colitis|2016Cited by 73